| WAT |
Report |
Q2 2026 adjusted diluted EPS |
BEAT |
pred ~$3.09 vs. cons $3.01 |
MEDIUM |
| WAT |
Report |
Q2 2026 total reported revenue |
BEAT |
pred ~$1.648B vs. cons $1.620B |
MEDIUM |
| WAT |
Report |
Q2 2026 legacy organic constant-currency growth |
BEAT |
pred ~8.2% vs. cons 7.0% |
LOW |
| WAT |
Guide |
Total reported revenue |
BETTER |
guide ~$6.47B vs. cons $6.44B (FY2026) |
MEDIUM |
| WAT |
Guide |
Adjusted diluted EPS |
BETTER |
guide ~$14.60 vs. cons $14.50 (FY2026) |
MEDIUM |
| WAT |
Guide |
Adjusted diluted EPS |
BETTER |
guide ~$3.95 vs. cons $3.91 (Q3 2026) |
LOW |
| WAT |
Return |
Day-1 residual (stock − beta × S&P 500) |
+4.2% |
— |
MEDIUM |
| WAT |
Return |
5-day cumulative residual |
+2.0% (FADE) |
A Q2 beat and modest FY2026 raise should lift the shares initially, but guide ~$14.60 vs. cons $14.50 leaves implied H2 adjusted EPS of only ~$8.81 vs. cons ~$8.79 after the predicted Q2 beat, limiting subsequent estimate revisions. |
MEDIUM |